Viridian Therapeutics (VRDN)

• Market cap: $2.62B
• 1 day: -0.22%
• 5 days: 16.77%
• 1 month: 30.67%
• 3 months: 66%
• 6 months: 123.27%
• Year to date: 38.87%
• 1 year: 11.05%
• 5 years: 61.89%
• 10 years: -85.84%
• Sector: Healthcare
• Industry: Biotechnology

About: Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Employees: 143